Compare GBAB & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GBAB | CUVL |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Australia |
| Employees | N/A | 16 |
| Industry | Investment Managers | Miscellaneous |
| Sector | Finance | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.7M | 374.2M |
| IPO Year | 2010 | N/A |
| Metric | GBAB | CUVL |
|---|---|---|
| Price | $13.81 | $6.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 104.9K | 6.2K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.51 | $6.20 |
| 52 Week High | $15.94 | $8.20 |
| Indicator | GBAB | CUVL |
|---|---|---|
| Relative Strength Index (RSI) | 44.82 | 39.75 |
| Support Level | $13.70 | N/A |
| Resistance Level | $14.24 | $7.04 |
| Average True Range (ATR) | 0.16 | 0.34 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 20.00 | 0.00 |
Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust is a diversified closed-end management investment company. Its investment objective is to provide current income with a secondary objective of long-term capital appreciation. Its products include Mutual funds, Unit investment trusts, Closed-end funds, Rydex funds, Credit income fund and others.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.